You are here:

MS in the media - 22 December 2017

Published on

16 - 22 December 2017

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts

NICE recommends restricting choice of MS drugs

NICE has published a draft recommendation that Extavia be available on the NHS in England but not the other four beta interferon drugs (Avonex, Betaferon, Plegridy, Rebif) or Copaxone (glatiramer acetate). NICE found that all six drugs were effective and the decision is based on cost effectiveness. To help with our response, the MS Trust is collecting comments from people affected by this proposed change

Source: NICE
Source: Pharmaphorum

MS Trust link: NICE recommends Extavia, but rejects Copaxone, Avonex, Betaferon, Plegridy and Rebif

MS treatment optimism

A UK neurologist looks at how the treatment of MS has developed over the last 25 years. As he starts a trial for a drug called bexarotene he looks forward to the potential of repairing damage to nerves.

Source: Huffington Post

MS Trust link: MS research updates

Having MS and other conditions

A Canadian study found that people with three or more other conditions (comorbidities) were more likely to have relapses in the next two years. The most common comorbidities were anxiety, depression, high blood pressure, migraine and hyperlipidemia (high cholesterol). Migraine and hyperlipidemia were particularly associated with increased relapse risk

Source: MS News Today

MS Trust link: MS research updates

Criteria for diagnosing MS updated

An updated version of the McDonald criteria for diagnosing MS have been published in the Lancet. The new criteria allow for more use of data from lumbar punctures and increase the type and location of lesions seen on MRI scans that can be considered

Source: National MS Society (USA)

MS Trust link: McDonald criteria

Print this page